Key result
Current and future therapies for systolic heart failure include established neuro-hormonal blockers and mechanical devices, alongside novel emerging targets such as BET and PDE9A inhibition.
This review summarizes current and emerging therapeutic options for the management of systolic heart failure.
Advanced HF therapies improve survival; leaves open optimal device selection for end-stage disease.
Heart failure is a complex pathological condition characterized by the reduction in the ability of heart to pump blood to peripheral organs. There has been considerable advancement in the management of heart failure, and the disease modifying therapeutic options available currently have managed to enhance survival of HF patients. Use of advanced therapies and mechanical devices as a bridge to transplant (or even as definitive therapy for end-stage failure) is a standard practice. However, the mechanisms driving progression of heart failure is not well understood, and there is increasing realization that traditional models have been inadequate in explaining the progression of heart failure. Therefore, considerable interest has been generated to search for alternate models that might better explain and/or offer more targeted disease modifying agents. In this review, we discuss the currently available options for the management of systolic heart failure and new promising targets that may advance the paradigm of heart failure therapeutics.
No takes yet. Share an insight, caveat, or question.
A 2015 study conducted a review in Systolic heart failure. Heart failure therapies was evaluated. Current and future therapies for systolic heart failure include established neuro-hormonal blockers and mechanical devices, alongside novel emerging targets such as BET and PDE9A inhibition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: